Cancer Weekly back issues from November 2002:
DNAzymes act as cancer fighting agents.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Man-made agents described as DNAzymes could some day be major players in the fight against cancer. Researchers in Baltimore, Maryland recently explained in the journal Cancer Research how they ...
Das-1 immunostain distinguishes some classes of liver tumors from others.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Das-1 immunostain can distinguish between different types of liver tumors, according to a study conducted at a Pennsylvania University. In one of the few studies of its kind, researchers at ...
OSU studies risk related to beef consumption.(Ohio State University, breast cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Scientists concerned that a growth promoter widely used in the U.S. cattle industry may increase the risk of breast cancer are launching the first-ever study comparing beef consumption with elevated levels of zeranol in women's blood, urine and ...
Cytokine may play role in gastric carcinoma angiogenesis.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A new study has revealed a link between interleukin-6 and gastric cancer angiogenesis. Though interleukin (IL)-6 and the angiogenesis modulator vascular endothelial growth factor (VEGF) are both ...
P53 suppressor gene studied.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Montefiore Medical Center researchers are studying a new drug that has the potential to fight recurrent and highly resistant head and neck cancer. Montefiore is the only medical center in New York City involved in the phase III, ...
IMRT promising for treatment with minimal side effects.(intensity-modulated radiation therapy)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Intensity-modulated radiation therapy (IMRT) promises to be superior to conventional radiation therapies for the treatment of Hodgkin disease, according to a new study presented at the American Society for Therapeutic Radiology and Oncology's ...
Genetic findings in monkey herpes virus could aid research in human cancer.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- For the first time, scientists at the University of North Carolina (UNC) at Chapel Hill have discovered similar gene activity profiles between a herpes virus that affects rhesus macaque monkeys and a human herpes virus linked to Kaposi sarcoma. ...
Conventional CT models not adequate for modeling lung tumors during breathing.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Conventional CT scans do not adequately take into account the way lung tumors move as patients breathe, according to a new study presented October 8, 2002, at the American Society for Therapeutic Radiology and Oncology's Annual Meeting in New ...
Cancer treatment developer names CFO, strengthens board of directors.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- ARC Pharmaceuticals, Inc., announced the appointment of Bruce Hay to the position of CFO. Hay, William Adams, and Dr. Jerry Gray have also been appointed to the board of directors. "We are pleased to have Hay, with his previous successes ...
Judy H. Chiao, MD, named VP, oncology clinical R&D of drug discovery company.(Aton Pharma, Inc.)(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Aton Pharma, Inc., a privately held biopharmaceutical company with the mission to discover and develop therapeutics for cancer and other diseases, announced that Judy H. Chiao, MD, has been promoted to vice president, oncology clinical research and ...
DTI-015 developer completes enrollment of phase I/II trial of the new drug.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Direct Therapeutics, Inc., a privately held drug development company, announced that it has concluded patient enrollment and treatment for its multicenter phase I/II study of DTI-015, a new chemotherapeutic drug designed for direct injection to ...
Avon Foundation awards $2.785M grant for research and education.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- To encourage and promote breast cancer research and education, particularly among young investigators in underserved countries, the American Association for Cancer Research (AACR) has been awarded a $2.785 million grant from the Avon Foundation. ...
Brachytherapy is an effective treatment.(for breast cancer)(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Brachytherapy is an effective modality of treatment for breast cancer, according to a new study presented at the American Society for Therapeutic Radiology and Oncology's Annual Meeting in New Orleans. In the study, 199 women with ...
FDA approves inclusion of gene test in Herceptin labeling.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) anticipates that more breast cancer patients will benefit from use of its Vysis PathVysion fluorescence in situ hybridization (FISH) test as a result of the U.S. Food and Drug Administration's (FDA) approval to include ...
Lumpectomy just as effective as mastectomy.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- New results from a long-term study of breast cancer patients reveal that patients who underwent lumpectomies fared just as well as patients who had mastectomies, according to a new study presented in October 2002, at the American Society for ...
Medical advice to women contradictory, confusing.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Call it the year of mixed messages: first came debate about mammography's value, then the news that long-term use of the hormones estrogen and progestin raise the risk of breast cancer and heart attacks after all. Now more headlines, ...
Plant-based estrogens and genetic variations in their breakdown to be studied.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- The role of plant-based estrogens in modifying breast cancer risk is the subject of a 5-year research study and intervention to be conducted by nutritional epidemiologists at the University at Buffalo (UB). The research will be funded by ...
Postmastectomy radiation reduces the risk of recurrence.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Radiation after mastectomy reduces recurrence rates for breast cancer patients, according to a new study at the American Society for Therapeutic Radiology and Oncology's Annual Meeting in New Orleans. Eighteen hundred patients were ...
Alfacell, NCI expand research collaboration.(National Cancer Institute)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Alfacell Corp. (ACEL) has expanded its research collaboration with the National Cancer Institute (NCI), one of the institutes of the National Institutes of Health (NIH) in Rockville, Maryland. Under the umbrella of this expanded ...
Company to challenge FDA delay of manufactured tamoxifen launch.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) has announced that it disagrees with a letter, received from the U.S. Food and Drug Administration (FDA), which retroactively alters the approval date of Barr's application for tamoxifen 10 mg tablets. ...
Investigational new drug applications filed for M-Vax, O-Vax.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Avax Technologies, Inc., (AVXT) announced the submission of investigational new drug applications (IND) for M-Vax and O-Vax, its AC Vaccine technology product candidates for the treatment of melanoma and ovarian cancers, with the U.S. Food and Drug ...
One day, nanotechnology could be used to track and kill cancer cells.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- A new, patented nanotechnology that one day may allow cancer patients to receive treatments through an MRI procedure in a doctor's office is being developed by scientists at the University at Buffalo's Institute for Lasers, Photonics and ...
Team challenges nature of phase I trials for evaluating antiangiogenic therapy.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - The members of a multinational research team have challenged the conventional strategies of phase I trials for evaluating antiangiogenic therapies targeting tumors. Given the heterogeneity of ...
Zentaris inks agreement with oncology-focused company for oral signal transduction modulator.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Access Oncology, Inc., of New York City announced at the Bear Stearns Healthcare Conference that it has entered into a definitive license agreement with Zentaris AG of Frankfurt, Germany to develop Perifosine, an alkylphospholipid with antitumor ...
Automated imaging company releases new clinical system.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Applied Imaging Corp. (AICX) announced the release of Ariol, the company's latest cellular imaging system. Ariol is a high-throughput system designed to automate and standardize the analysis of immunohistochemistry (IHC) and fluorescence ...
Combining chemotherapy, radiation therapy improves survival odds.(cervical cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- The updated results of a study confirm preliminary findings that chemotherapy can increase the chances of survival for some cervical cancer patients, according to a new study presented at the October 2002 American Society for Therapeutic Radiology ...
New treatment for sexual dysfunction.(in cervical cancer patients)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Cervical cancer patients who were treated with radiation therapy now have a new tool for fighting sexual side effects, according to a new study presented in October 2002 at the American Society for Therapeutic Radiology and Oncology's Annual ...
Women with advanced disease need varied therapy, study shows.(cervical cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Researchers at Washington University School of Medicine in St. Louis have found that women with advanced cervical cancer have different odds of survival depending on how far the cancer has spread, as determined by an imaging technique called ...
Data reported from preclinical DACH platinum study in mice.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc. (AKC) reported data at the 2nd International Symposium on Tumor Targeted Delivery Systems indicating its experimental compound, AP5346, in the B16 murine melanoma model, resulted in significantly superior tumor growth ...
Vitamin-mediated tumor targeting data confirm enhanced drug uptake.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc. (AKC) presented at the 2nd International Symposium on Tumor Targeted Delivery Systems in vitro and in vivo data on vitamin targeted polymers. Linking drugs to polymers increases the circulation time of cancer ...
CRO announces services agreement with MedImmune.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- BioReliance Corp. (BREL) announced that it has entered into a laboratory services agreement with MedImmune, Inc. Under the agreement, BioReliance will perform a range of assays for certain of MedImmune's development-stage or commercial ...
Controlled tissue resection system minimizes collateral tissue damage.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- ACMI announced it has received an excellent response from surgeons using its Vista CTR (Controlled Tissue Resection) system for performing bipolar resection of the prostate and bladder tumors (TURP/TURBT). The Vista CTR system combines ...
Company licenses TransMID product to Nycomed.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- KS Biomedix Holdings, plc, (KSB) has appointed Nycomed as the European licensee for its TransMID product in a licensing agreement worth up to $60 million. TransMID is a biopharmaceutical product in development for the treatment of high ...
High-risk tumors largely resist chemotherapy attack.(head and neck cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Adding chemotherapy to radiation therapy and surgery failed to significantly improve control of high-risk, resected head and neck cancers, according to a new study presented at the October 2002 American Society for Therapeutic Radiology and ...
European trial finds old lung cancer treatment may still be best.(cisplatin)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- The first clinical trial to compare directly two of the most widely used drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) - have concluded that the older drug, cisplatin, is the better treatment. ...
Combination of gene-loaded vectors suppresses human skin cancer.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A combination of gene therapies has produced highly beneficial results in murine models of human melanoma. Scientists report melanoma has become one of the most commonly diagnosed forms of ...
Study finds declines in 20- to 44-year-olds.(in melanoma death rates)(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- U.S. melanoma deaths dropped significantly in people ages 20 to 44 years over the past 3 decades, thanks in part to educational campaigns about the dangers of too much sun, researchers say. The decline among young adults in deaths from ...
Cancer survival rates higher than previously assumed.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Conventional estimates for life expectancy after cancer diagnosis have been too pessimistic, suggests a study in the Lancet. There are two main ways of quantifying survival estimates after cancer diagnosis. The conventional method, ...
FDA awards EntreMed orphan drug grant for Endostatin trial.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc. (NASDAQ:ENMD), which focuses on angiogenesis research and product development, announced it received notification that it has been awarded a clinical research grant from the U.S. Food and Drug Administration's (FDA) Office of Orphan ...
Combining ionizing radiation and radioimmunotherapy appears safe.(for non-Hodgkin lymphoma)(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Combining external beam radiotherapy and the immunotherapy drug Zevalin appears to be a safe and effective treatment for patients with some of the most common types of non-Hodgkin lymphoma, according to a new study presented at the American Society ...
Company updates RSR13 phase II study results.(for non-small cell lung cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced updated positive survival results from a phase II clinical trial evaluating the use of RSR13 (efaproxiral) in patients with locally advanced, unresectable, non-small cell lung cancer receiving thoracic ...
Patient recruitment target reached in pivotal trial of pemtumomab.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Antisoma plc, a biopharmaceutical company based in Britain, announced it has reached the target for patient recruitment in its pivotal phase III study of pemtumomab in ovarian cancer. Four hundred and twenty patients have been enrolled ...
Phase III clinical results for 4-month product reported.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc. (NASDAQ:ATRX) announced the presentation of phase III clinical results for the company's Eligard 30 mg (leuprolide acetate for injectible suspension) prostate cancer treatment at the 9th Annual CaP CURE Scientific Retreat. ...
Spice may protect skin during treatment for cancer.(curry)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Cancer researchers at the University of Rochester Medical Center have found that curcumin, a substance in curry long believed to have health benefits, seems to protect skin during radiation therapy. Doctors said that while further study is needed, ...
Looking at sphincter preservation and quality of life.
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Roxanna Guilford, senior medical writer - A study of 130 rectal cancer patients treated with neoadjuvant chemoradiation reveals that there is no quality of life difference between those who received low anterior resection (LAR) or ...
Company restructures AxCell subsidiary to support oncology focus.(Brief Article)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- Cytogen Corp. (CYTO), a biopharmaceutical company with an established and growing product line in oncology, announced a realignment of its AxCell Biosciences subsidiary in an effort to reduce expenses and position Cytogen for stronger long-term ...
Researchers find promising preliminary results from gene therapy.(thyroid cancer)
Nov 05, 2002 ... 2002 NOV 5 - (NewsRx.com & NewsRx.net) -- by Roxanna Guilford, senior medical writer - Research by University of Pennsylvania -Philadelphia offers potential promise for thyroid cancer patients, especially those with tumors resistant to iodine therapy. There's now no effective ...
Natural insecticide identified as potential cancer prevention agent.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- The use of deguelin, a natural plant extract most commonly used as an insecticide in Africa and South American, inhibits the growth of precancerous and cancerous lung cells, with no toxic effects on normal cells, according to a study presented at ...
Antibody halts tumor growth in prostate cancer model.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Tumors in animal models of androgen-independent human prostate cancer stop growing almost completely when treated with paclitaxel and antibody to vascular endothelial growth factor (VEGF). ...
Gene-attenuated viruses demonstrate anticancer effect.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Different combinations of E1B gene deletions can make genetically altered adenoviruses attractive candidates for cancer gene therapy. "For the aim of improving adenoviral vectors for cancer gene ...
Pain control possible with gene therapy.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- By "programming" a herpes simplex virus to deliver a gene-mediated pain-blocking protein at the cellular level, University of Pittsburgh researchers have been able to significantly reduce cancer-related pain in mice with tumors. Their ...
Type 2 diabetes increases breast cancer risk.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The large Atherosclerosis Risk in Communities (ARIC) study yielded data that indicate women with type 2 diabetes have a slightly higher risk of developing breast cancer than women without ...
Vaccine effective against melanoma in mice.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Immunization with a vaccine containing mouse fibroblasts transfected with DNA from B16 mouse melanoma cells that expressed syngeneic and allogeneic major histocompatibility complex (MHC) class I ...
Desperation drives patients to alternative remedies.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Oncologists have been urged to be more responsive to cancer patients who want to try alternative medicines. Speaking October 18, 2002, at the European Society for Medical Oncology Congress in Nice, France, Professor Edzard Ernst from ...
Phase II preclinical tests to commence for nanoparticle-based technology.(Brief Article)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Advectus Life Sciences, Inc., has been advised by the University of North Carolina Brain Tumor Center at Chapel Hill as to the schedule details of the second phase of the preclinical study of its patented nanoparticle based technology (Nanocure ...
20% of mammogram-detected cancers are in situ lesions of unknown aggressiveness.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Of cancers detected by screening mammography, approximately 20% are ductal carcinoma in situ (DCIS), a noninvasive tumor contained within the walls of the breast duct, according to a multistate study led by University of California San Francisco ...
COX-2 inhibitors may delay onset.(of breast cancer)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- The use of a selective COX (cyclooxygenase)-2 inhibitor (celecoxib) significantly reduced the incidence of breast cancer in HER-2/neu overexpressing mice, according to a study presented October 15, 2002, at the American Association for Cancer ...
Doctors surprised that older women patients can tolerate powerful treatment.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Oncologists may be anxious about treating older women with breast cancer in the same way that they would treat younger patients, but research conducted at the Institute Paoli Calmettes in Marseilles, France, has shown that older patients can ...
FDA marketing authorization received for imaging technology.(Brief Article)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Instrumentarium Imaging, a division of Instrumentarium , announced that the U.S. Food and Drug Administration has cleared the Delta 32 and Delta 32 TACT diagnostic digital breast imaging systems for marketing in the U.S. Delta 32 and ...
Maternal alcohol use during pregnancy may increase offspring's risk.(of breast cancer)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Women who drink moderate-to-high quantities of alcohol during pregnancy could be contributing to an increased risk of breast cancer among their daughters, according to a study presented at the first annual Frontiers in Cancer Prevention Research ...
Short-term estrogen may offer protection.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Short-term use of pregnancy-level estrogen, designed to mimic pregnancy, is highly effective in protecting women from breast cancer, according to a study presented at the American Association for Cancer Research's first annual Frontiers in Cancer ...
Study finds no link to deodorant use.(breast cancer)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- A new study, prompted by an urban myth spread on the Internet, shows there is no evidence that antiperspirants or deodorants can cause breast cancer. The study, appearing in the Journal of the National Cancer Institute, examined the ...
Key patent obtained for p53 targeted chemotherapy.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Introgen Therapeutics, Inc., (INGN) and the University of Texas M.D. Anderson Cancer Center announced that the U.S. Patent and Trademark Office has issued to the Board of Regents of the University of Texas System U.S. Patent No. 6,410,029 entitled ...
Agreement reached for development, commercialization of indolocarbazole.(Brief Article)
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Banyu Pharmaceutical Co. Ltd., and Pharmacia Corporation (PHA) announced that they have signed an agreement for the development and commercialization of Banyu's proprietary anticancer compound J-107088 on a worldwide basis excluding Japan. ...
Alpha particle immunotherapy collaboration formed.
Nov 12, 2002 ... 2002 NOV 12 - (NewsRx.com & NewsRx.net) -- Actinium Pharmaceuticals, Inc., (API) announced its collaboration with Memorial Sloan-Kettering Cancer Center (MSKCC) in the field of alpha particle immunotherapy (APIT) by signing a license, development, and commercialization agreement. ...